Bain Capital Life Sciences Partners, LP

CIK 1703030 · last filed 2026-05-22

Bain Capital Life Sciences Partners, LP is a corporate insider who has filed 4 SEC Form 4 insider transactions across 3 companies since 2017. The most recent filing, for RPID, was dated May 22, 2026. Across all open-market trades the lifetime net is −$159.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $10.4M across reported positions. The firm reports its address in Boston, MA. 22 SEC filings were submitted jointly with BCIP Life Sciences Associates, LP.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$10.37M

Companies

3

Total Filings

4

Lifetime Open-Market Net

-$159.35M

Filer Profile

Reported Address

200 CLARENDON STREET
BOSTON, MA 02116

Phone

(617) 516-2878

State of Incorporation

Cayman Islands

Related Filers

BCIP Life Sciences Associates, LP — 22 joint filings, latest 2026-05-22

Bain Capital Life Sciences Investors, LLC — 22 joint filings, latest 2026-05-22

Bain Capital Life Sciences Fund, L.P. — 19 joint filings, latest 2026-05-22

Jeffrey Lawrence Schwartz — 16 joint filings, latest 2021-07-21

Adam Koppel — 15 joint filings, latest 2021-07-21

BCLS II Investco, LP — 3 joint filings, latest 2025-02-21

Bain Capital Life Sciences Fund II, L.P. — 3 joint filings, latest 2025-02-21

Bain Capital Life Sciences Investors II, LLC — 3 joint filings, latest 2025-02-21

Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
RPID	10%+ Owner	8,434,560	$1.23	$10.37M	$0	1	2026-05-22
Aptinyx Inc. (APTX) Delisted	10%+ Owner	8,891,758	$0.06	$542.4K	$60.00M	1	2020-10-27
Dicerna Pharmaceuticals Inc (DRNA) Delisted	Director	5,580,237	$38.22	$213.28M	-$219.34M	2	2019-11-21

Recent Filings

4 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2026-05-22	RPID	Buy (P)	—	$0	EDGAR
2020-10-27	Aptinyx Inc. (APTX) Delisted	Buy (P)	+19,999,998	$60.00M	EDGAR
2019-11-21	Dicerna Pharmaceuticals Inc (DRNA) Delisted	Sell (S)	−10,500,000	-$231.31M	EDGAR
2017-12-19	Dicerna Pharmaceuticals Inc (DRNA) Delisted	Mixed	+53,581,422	$11.97M	EDGAR

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.